MARKER THERAPEUTICS INC (MRKR) Stock Price, Quote, News and Overview
NASDAQ:MRKR - Nasdaq - US57055L2060 - Common Stock - Currency: USD
MRKR Quote, Performance and Key Statistics
NASDAQ:MRKR (2/21/2025, 8:00:01 PM)
1.57
-0.06 (-3.68%)
The current stock price of MRKR is 1.57 USD. In the past month the price decreased by -32.33%. In the past year, price decreased by -60.15%.
MRKR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About MRKR
Company Profile
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 8 full-time employees. The company went IPO on 2016-11-08. The firm specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The company has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. The company is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). The company has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Company Info
MARKER THERAPEUTICS INC
2450 Holcombe Blvd, Suite Bcm-A, Ms: Bcm251
Houston TEXAS 77027 US
CEO: Peter Hoang
Employees: 8
Company Website: https://markertherapeutics.com/
Investor Relations: https://www.markertherapeutics.com/investors/
Phone: 17134006400
MARKER THERAPEUTICS INC / MRKR FAQ
What is the stock price of MARKER THERAPEUTICS INC today?
The current stock price of MRKR is 1.57 USD. The price decreased by -3.68% in the last trading session.
What is the ticker symbol for MARKER THERAPEUTICS INC stock?
The exchange symbol of MARKER THERAPEUTICS INC is MRKR and it is listed on the Nasdaq exchange.
On which exchange is MRKR stock listed?
MRKR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MARKER THERAPEUTICS INC stock?
7 analysts have analysed MRKR and the average price target is 11.73 USD. This implies a price increase of 647.13% is expected in the next year compared to the current price of 1.57. Check the MARKER THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MARKER THERAPEUTICS INC worth?
MARKER THERAPEUTICS INC (MRKR) has a market capitalization of 16.81M USD. This makes MRKR a Nano Cap stock.
How many employees does MARKER THERAPEUTICS INC have?
MARKER THERAPEUTICS INC (MRKR) currently has 8 employees.
What are the support and resistance levels for MARKER THERAPEUTICS INC (MRKR) stock?
MARKER THERAPEUTICS INC (MRKR) has a support level at 1.56 and a resistance level at 1.72. Check the full technical report for a detailed analysis of MRKR support and resistance levels.
Should I buy MARKER THERAPEUTICS INC (MRKR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MRKR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MRKR, evaluating the profitability, health, valuation and growth aspects
- MARKER THERAPEUTICS INC (MRKR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MARKER THERAPEUTICS INC (MRKR) Sales and EPS estimates to see what analysts future expectations are.
- MARKER THERAPEUTICS INC (MRKR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MARKER THERAPEUTICS INC (MRKR) Insider and Institutional Ownership to learn about the owners and their transactions.
- MARKER THERAPEUTICS INC (MRKR) Stock Chart to make your own analysis
- MARKER THERAPEUTICS INC (MRKR) Latest news and press-releases to stay up to date.
Does MARKER THERAPEUTICS INC (MRKR) stock pay dividends?
MRKR does not pay a dividend.
When does MARKER THERAPEUTICS INC (MRKR) report earnings?
MARKER THERAPEUTICS INC (MRKR) will report earnings on 2025-03-24, after the market close.
What is the Price/Earnings (PE) ratio of MARKER THERAPEUTICS INC (MRKR)?
MARKER THERAPEUTICS INC (MRKR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.08).
What is the Short Interest ratio of MARKER THERAPEUTICS INC (MRKR) stock?
The outstanding short interest for MARKER THERAPEUTICS INC (MRKR) is 2.41% of its float. Check the ownership tab for more information on the MRKR short interest.
MRKR Technical Analysis
MRKR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MRKR. While MRKR seems to be doing ok healthwise, there are quite some concerns on its profitability.
MRKR Financial Highlights
Over the last trailing twelve months MRKR reported a non-GAAP Earnings per Share(EPS) of -1.08. The EPS decreased by -0.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -88.88% | ||
| ROE | -130.17% | ||
| Debt/Equity | 0 |
MRKR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to MRKR. The Buy consensus is the average rating of analysts ratings from 7 analysts.